AstraZeneca’s Lynparza: US FDA Frowns Upon ‘All Comers’ Indication In First-Line Prostate Cancer

 
• By Sue Sutter
  
Narrow opening in rocks
ODAC will consider whether AstraZeneca's proposed indication in first-line mCRPC should be narrowed to patients with tumor BRCA mutations. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers